Genetic Technologies

Genetic Technologies Ltd. is a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. It operates through EasyDNA and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The GeneType/Corporate segment includes tha GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

Earnings data Q3 2024

Genetic Technologies Ltd. operates as a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. It operates through EasyDNA, AffinityDNA and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The AffinityDNA segment focuses on AffinityDNA branded test sales and expenses.The GeneType/Corporate segment includes the GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

MELBOURNE, Australia, April 19, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies"), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of 1,000,000 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Company, at a purchase price of $2.00 per ADS. In addition, in a concurrent private placement, the Company will issue unregistered warrants ("Warrants") to purchase up to 1,000,000 ADSs.

Genetic Technologies Announces $2 Million Registered Direct Offering

BioVie Inc

ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern Time (ET).

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MELBOURNE, Australia, April 02, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to report the company's new digital strategy, led by the company's recently appointed strategic advisor, Dr. Malcolm Bohm, is having a significant positive impact across all facets of GTG's social media platforms.

Genetic Technologies' Digital Strategy Ignites Significant Traction in US Market

MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), is pleased to announce the launch of a wide-reaching customer – targeted digital advertising campaign in the United States. This comprehensive program will drive Consumer Initiated Testing (CIT) for the company's geneType Risk Assessment Tests. The campaign will commence end of March 2024 and will scale up throughout the remainder of the year. The U.S. wellness testing market is projected to reach $4.9 billion by 2032 from $878.9 million in 2022 with an annual growth rate of 18.86%1. GTG's strategy ensures that the company's geneType Risk Assessment test portfolio will be able to access this segment of this rapidly growing market in the U.S.2

GTG to launch U.S. Customer Digital Media Sales Campaign

MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness, and serious disease, advises that it has received formal notice from the Nasdaq Stock Market, LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As previously disclosed, the Company received a written notice from Nasdaq on July 17, 2023, notifying the Company that it had failed to meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market.

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

ORLANDO, FL / ACCESSWIRE / December 29, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET).

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

MELBOURNE, Australia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, announced today its plans to effect:

Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change

MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of a peer-reviewed research paper validating geneType's Pancreatic Cancer risk assessment test.

GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment

Knightscope

Soligenix

ORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (Nasdaq:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) on The RedChip Small Stocks Big Money Show®, a sponsored program on Bloomberg TV, this Saturday, October 7, at 7 p.m. Eastern Time (ET).

Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

MELBOURNE, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce a partnership with the Gold Coast Private Hospital (GCPH), a member of Healthscope, to establish a Precision Medicine Clinic at the hospital.

GTG Signs Precision Medicine Pilot with Australia's Largest Private Hospital Network

American Resources Corp

ORLANDO, FL / ACCESSWIRE / September 15, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (OTC:ARDS), Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE), and American Resources Corporation (Nasdaq:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 16, at 7 p.m. Eastern Time (ET).

Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice

GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner

MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (Nasdaq: GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ: SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TV

60 Degrees Pharmaceuticals Inc

ORLANDO, FL / ACCESSWIRE / September 1, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (Nasdaq:GENE) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET).

Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

MELBOURNE, Australia, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2023.

Annual Results – Momentum Building on our Commercial Plans

Cardio Diagnostics Holdings In

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced the successful completion of an employer-sponsored heart disease fair in Kansas, United States.

Cardio Diagnostics Partners With FRSTeam of East Kansas and West Missouri to Host First Onsite Heart Disease Fair in Kansas Using Epigenetic-Genetic Technologies

Genetic Technologies Limited (NASDAQ:GENE ) Q4 2023 Earnings Conference Call August 8, 2023 7:15 PM ET Company Participants Adrian Mulcahy - Investor Relations Simon Morriss - Chief Executive Officer Tony Di Pietro - Chief Financial Officer Carl Stubbings - Chief Commercial Officer Conference Call Participants Adrian Mulcahy Thank you for joining us, and afternoon for those joining us from the U.S. I'm really pleased to have both Simon Morriss, the Chief Executive Officer of Genetic Technologies; and Tony Di Pietro, the CFO of Genetic as well. So this morning, we are going to go through an Investor Update.

Genetic Technologies Limited (GENE) Q4 2023 Earnings Call Transcript

MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness and serious disease, advises that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, since the closing bid price for the Company's American Depositary Shares (ADS) on the Nasdaq Capital Market was below US$1.00 for 34 consecutive trading days. Nasdaq Listing Rule 5550(a)(2) requires the ADS to maintain a minimum bid price of US$1.00 per share (the “Minimum Bid Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that failure to meet such requirement exists if the deficiency continues for a period of 30 consecutive business days.

Genetic Technologies Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Genetic Technologies Limited (NASDAQ:GENE ) Q3 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Adrian Mulcahy - Investor Relations Simon Morriss - Chief Executive Officer Tony Di Pietro - Chief Financial Officer Conference Call Participants Adrian Mulcahy [Abrupt Start] FY 2023. I'm really pleased to have both Simon Morriss, the CEO; and Tony Di Pietro.

Genetic Technologies Limited (GENE) Q3 2023 Earnings Call Transcript

MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the publication of a research paper in the peer-reviewed journal Melanoma Research validating the geneType for Melanoma risk assessment test in one of the most commonly diagnosed cancers in the Western world, 3rd in Australia and 5th in the United States.

New Publication Validates geneType for Melanoma Risk Assessment

MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of another research paper supporting the utilisation of geneType Breast Cancer Risk Assessment Test in the peer-reviewed journal Cancer Prevention Research.

Back-to-back Studies Validate geneType Breast Cancer Risk Test

Genetic Technologies Limited (NASDAQ:GENE ) Q2 2023 Earnings Conference Call February 27, 2023 5:00 PM ET Company Participants Adrian Mulcahy - Investor Relations Simon Morriss - CEO Tony Di Pietro – CFO Carl Stubbings - Chief Commercial Officer Conference Call Participants Adrian Mulcahy

Genetic Technologies Limited (GENE) Q2 2023 Earnings Call Transcript

MELBOURNE, Australia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced the closing of its previously announced registered direct offering with several institutional investors for the purchase and sale of 3,846,155 American Depositary Shares (“ADSs”), each representing six hundred (600) ordinary shares of the Company, at a purchase price of $1.30 per ADS.

Genetic Technologies Announces Closing of $5 Million Registered Direct Offering

Express

Muscle Maker

Omeros

SoundHound AI Inc

Penny stocks to watch with big news this week. The post Best Penny Stocks To Buy: 5 To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy: 5 To Watch With Big News This Week

MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is delighted to provide further update.

News for Genetic Technologies Stock (GENE)